Patients infected with hepatitis C virus (HCV) are at high risk for the development of liver cirrhosis or liver cancer. Early detection and treatment, particularly with new direct-acting antiviral (DAA) therapies, are the keys to improved outcomes. But high costs and insurance issues continue to limit access to both diagnosis and treatment for many patients.
In our hepatology coverage this year, Medical Economics chronicled the main issues, new studies, and treatment advances that impact our readers’ business and clinical practice. Click through the slides (above/below) for a quick review of efforts to remove obstacles to optimal care for patients infected with HCV.